Q32 Bio director granted 10,826 stock options

Q32 Bio Inc. director Mark T. Iwicki reported a compensation award of stock options for 10826.0000 shares of common stock, granted on June 12, 2026 at an exercise price of $12.6400 per share and expiring June 11, 2036.

Rhea-AI Filing Summary

Q32 Bio Inc. director Mark T. Iwicki reported a compensation award of stock options for 10826.0000 shares of common stock, granted on June 12, 2026 at an exercise price of $12.6400 per share and expiring June 11, 2036. The options vest in full on the earlier of June 12, 2027 or the issuer's next annual meeting of stockholders, subject to his continued service. This Form 4 amendment corrects the number of options previously reported for this grant.

Insider Trade Summary

Grant/Award: 10,826 shares

Grant/Award 1 txn

Insider Iwicki Mark T

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1, F2	10,826	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 10,826 contracts (Direct)

Footnotes (2)

1. F1. This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026.
2. F2. The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.

Key Figures

Options granted: 10826.0000 shares Exercise price: $12.6400 per share Underlying shares: 10826.0000 shares +2 more

5 metrics

Options granted 10826.0000 shares Stock option award to director on June 12, 2026

Exercise price $12.6400 per share Conversion or exercise price of the stock option

Underlying shares 10826.0000 shares Common stock underlying the reported stock option

Option expiration 2036-06-11 Expiration date of the reported stock option grant

Vesting date trigger 2027-06-12 Latest vesting date, or earlier on next annual stockholders meeting

Key Terms

Stock Option (Right to Buy), exercise price, vest and become exercisable, annual meeting of stockholders

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 12.6400"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest and become exercisable financial

"The shares underlying this option shall vest and become exercisable in full"

annual meeting of stockholders regulatory

"earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Q32 Bio (QTTB) report for Mark T. Iwicki?

Q32 Bio reported a grant of stock options to director Mark T. Iwicki covering 10826.0000 shares of common stock. The options were awarded on June 12, 2026 as equity compensation, not a market purchase or sale, and are reported as a derivative security acquisition.

What are the key terms of Mark T. Iwicki’s QTTB stock option grant?

The option covers 10826.0000 shares of Q32 Bio common stock at an exercise price of $12.6400 per share, expiring on June 11, 2036. It is a right to buy common shares and was reported as directly owned derivative securities following the award.

How and when do Mark T. Iwicki’s QTTB options vest?

The options vest and become exercisable in full on the earlier of June 12, 2027 or Q32 Bio’s next annual meeting of stockholders. Vesting is expressly conditioned on Iwicki’s continued service with the company through the applicable vesting date.

Why did Q32 Bio (QTTB) file an amended Form 4 for this option grant?

The amended Form 4 was filed to correct the number of options previously reported as awarded to Mark T. Iwicki on June 12, 2026. The amendment states it is made solely to fix that option-count figure; no new transaction occurred on the amendment date.

Does this QTTB Form 4/A indicate any stock sales by Mark T. Iwicki?

No, the filing reports only a grant of stock options to Mark T. Iwicki and no share sales. The transaction code is “A” for an acquisition by grant or award, with exercise price set at $12.6400 per share and no sale-related transaction codes disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/21/2026 - 08:37 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Iwicki Mark T

(Last) (First) (Middle)

Q32 BIO INC.

830 WINTER STREET

(Street)

WALTHAM MASSACHUSETTS 02451

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Q32 Bio Inc. [ QTTB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
06/16/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$12.64	06/12/2026		A		10,826(1)		(2)	06/11/2036	Common Stock	10,826(1)	$0	10,826(1)	D

Explanation of Responses:

1. This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026.

2. The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.

	/s/ Eric Bell, Attorney-in-Fact	07/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)